ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 428,93
0,27%
Dow Jones
42 238,84
-0,14%
DAX
20 268,50
0,65%
Brent Oil
79,365
-1,14%
Bitcoin
95 620,61
1,18%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cartesian Therapeutics Inc (RNAC)

  7. Cartesian Therapeutics Inc (RNAC) Actualités

RNAC

Cartesian Therapeutics (RNAC)

Cartesian Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RNAC
DateHeureSourceTitreSymboleSociété
14/01/202506h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNACCartesian Therapeutics Inc
13/01/202522h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNACCartesian Therapeutics Inc
13/01/202513h00GlobeNewswire Inc.Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesNASDAQ:RNACCartesian Therapeutics Inc
10/01/202512h01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:RNACCartesian Therapeutics Inc
08/01/202522h38Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RNACCartesian Therapeutics Inc
08/01/202522h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RNACCartesian Therapeutics Inc
07/01/202513h05GlobeNewswire Inc.Cartesian Therapeutics Announces New Employment Inducement GrantsNASDAQ:RNACCartesian Therapeutics Inc
13/12/202422h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RNACCartesian Therapeutics Inc
10/12/202422h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNACCartesian Therapeutics Inc
03/12/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNACCartesian Therapeutics Inc
03/12/202412h00GlobeNewswire Inc.Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 TrialNASDAQ:RNACCartesian Therapeutics Inc
21/11/202413h00GlobeNewswire Inc.Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitNASDAQ:RNACCartesian Therapeutics Inc
07/11/202413h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNACCartesian Therapeutics Inc
07/11/202413h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNACCartesian Therapeutics Inc
07/11/202413h00GlobeNewswire Inc.Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RNACCartesian Therapeutics Inc
05/11/202415h00GlobeNewswire Inc.Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual MeetingNASDAQ:RNACCartesian Therapeutics Inc
15/10/202422h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RNACCartesian Therapeutics Inc
15/10/202413h00GlobeNewswire Inc.Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual MeetingNASDAQ:RNACCartesian Therapeutics Inc
09/09/202413h00GlobeNewswire Inc.Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisNASDAQ:RNACCartesian Therapeutics Inc
06/09/202413h05GlobeNewswire Inc.Cartesian Therapeutics Announces New Employment Inducement GrantNASDAQ:RNACCartesian Therapeutics Inc
03/09/202413h00GlobeNewswire Inc.Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15NASDAQ:RNACCartesian Therapeutics Inc
26/08/202413h00GlobeNewswire Inc.Cartesian Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:RNACCartesian Therapeutics Inc
08/08/202413h00GlobeNewswire Inc.Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RNACCartesian Therapeutics Inc
02/07/202422h05GlobeNewswire Inc.Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikNASDAQ:RNACCartesian Therapeutics Inc
02/07/202412h31GlobeNewswire Inc.Cartesian Therapeutics Announces $130 Million Private Placement Equity FinancingNASDAQ:RNACCartesian Therapeutics Inc
02/07/202412h31GlobeNewswire Inc.Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusNASDAQ:RNACCartesian Therapeutics Inc
02/07/202412h30GlobeNewswire Inc.Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia GravisNASDAQ:RNACCartesian Therapeutics Inc
22/05/202413h00GlobeNewswire Inc.Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia GravisNASDAQ:RNACCartesian Therapeutics Inc
13/05/202422h30GlobeNewswire Inc.Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:RNACCartesian Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RNACCartesian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAC

Dernières Valeurs Consultées

DOWI
DJISRLD
DJ Islamic Market Sri La...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés